Bronstein, Goertz & Grossman LLC

Bronstein, Goertz & Grossman LLC

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) — Lawyer Announcement – Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain of its officers.

Category definition:

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired BioVie securities between August 5, 2021 and November 29, 2023, inclusive (the “Class Period”). ). These investors are encouraged to join this case by visiting the company’s website: bgandg.com/BIVI.

Case details:

The Complaint alleges that Defendants misrepresented and failed to disclose the following adverse facts relating to BioVie’s business, operations, and prospects, which were known to Defendants or recklessly ignored. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the ongoing COVID-19 pandemic caused “limited access” to clinical trial sites, which significantly impacted the Company’s ability to Conduct appropriate oversight of clinical trials; (2) due to “limited access” to clinical trial sites, the trial was at greater risk of “significant deviation from protocol, violations of good clinical practice (GCP)” and “anomalous data”; (3) the Company was experiencing issues with the contract research organizations it retained, which increased the risk that the trial would not comply with Google Cloud Platform programs; (4) the company identified “higher than expected levels of deviation” in the data; (5) because of the “highly unusual level of suspected irregularities” there was an increased risk that the majority of clinical trial subjects would be excluded; (6) As a result of the exclusions, there was a materially increased risk that the clinical trial “would not achieve statistical significance.” and (7) as a result of the foregoing, statements regarding BioVie’s business, operations, prospects, and/or compliance with the GCP were false, misleading, and/or lacked a reasonable basis at all relevant times.

What then?

A class action lawsuit has already been filed. If you would like to review a copy of the complaint, you can visit the company’s website: bgandg.com/BIVI Or you may contact Peretz Bronstein, Esq. Or our law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffer a loss in BioVie, you have until March 19, 2024 to ask the court to appoint you as lead plaintiff. Your ability to participate in any recovery does not require that you serve as lead plaintiff.

There is no cost to you

We represent investors in class actions on a contingency fee basis. This means that we will ask the court to reimburse us for out-of-pocket expenses and attorney fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Goertz and Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud and shareholder derivative litigation. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Lawyer advertisement. Previous results do not guarantee similar results.

communication:

Bronstein, Goertz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

332-239-2660 | info@bgandg.com

    (Tags for translation)Bronstein

You may also like...

Leave a Reply